A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 586 participants.

Also called NCT07112339

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 586 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07112339
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada, Germany, Italy (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07112339. Randomized; no masking; primary purpose treatment. Start 2025-08-15 (actual); primary completion 2028-03-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin icodec
Intervention (Drug)
Basal insulin analogues
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07112339
Content hash
8ea61755c9c91e002952a6b958004ec40856f27068c408b9d7e21a78fa8e7df1